omeprazole has been researched along with Lymphoma, Non-Hodgkin in 8 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Bortezomib, an antineoplastic for the treatment of relapsed multiple myeloma and mantle cell lymphoma, undergoes metabolism through oxidative deboronation by cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C19." | 9.14 | Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ( Acharya, M; Britten, CD; Chan, K; Cohen, N; Dudov, A; Fuloria, J; Gabrail, N; Nemunaitis, J; Quinn, DI; Yee, L, 2009) |
| "Bortezomib, an antineoplastic for the treatment of relapsed multiple myeloma and mantle cell lymphoma, undergoes metabolism through oxidative deboronation by cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C19." | 5.14 | Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ( Acharya, M; Britten, CD; Chan, K; Cohen, N; Dudov, A; Fuloria, J; Gabrail, N; Nemunaitis, J; Quinn, DI; Yee, L, 2009) |
| "pylori treatment on MALT lymphoma and chronic gastritis at the histologic and molecular levels." | 1.31 | Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases. ( Begum, S; Endo, H; Kawamata, H; Sano, T; Urakami, Y, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Quinn, DI | 1 |
| Nemunaitis, J | 1 |
| Fuloria, J | 1 |
| Britten, CD | 1 |
| Gabrail, N | 1 |
| Yee, L | 1 |
| Acharya, M | 1 |
| Chan, K | 1 |
| Cohen, N | 1 |
| Dudov, A | 1 |
| Stolte, M | 4 |
| Eidt, S | 1 |
| Martin, J | 1 |
| Boyle, S | 1 |
| Jacyna, M | 1 |
| De Mas, CR | 1 |
| Seifert, E | 1 |
| Neubauer, A | 3 |
| Thiede, C | 2 |
| Begum, S | 1 |
| Sano, T | 1 |
| Endo, H | 1 |
| Kawamata, H | 1 |
| Urakami, Y | 1 |
| Morgner, A | 1 |
| Miehlke, S | 1 |
| Fischbach, W | 1 |
| Schmitt, W | 1 |
| Müller-Hermelink, H | 1 |
| Greiner, A | 1 |
| Schetelig, J | 1 |
| Ehninger, G | 1 |
| Bayerdörffer, E | 1 |
| Tankovic, J | 1 |
| Lamarque, D | 1 |
| Lascols, C | 1 |
| Soussy, CJ | 1 |
| Delchier, JC | 1 |
| Alpen, B | 1 |
| Röbbecke, J | 1 |
| Wündisch, T | 1 |
2 trials available for omeprazole and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
Topics: Aged; Anti-Ulcer Agents; Antineoplastic Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Bor | 2009 |
Helicobacter pylori eradication therapy in gastric high grade non Hodgkin's lymphoma (NHL).
Topics: Aged; Anti-Ulcer Agents; Clarithromycin; Combined Modality Therapy; Drug Therapy, Combination; Gastr | 2001 |
6 other studies available for omeprazole and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Healing gastric MALT lymphomas by eradicating H pylori?
Topics: Amoxicillin; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell; Lymp | 1993 |
Regression of a large gastric MALT lymphoma with antibiotic treatment to eradicate Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infec | 1997 |
[An unusual course of low-malignancy non-Hodgkin lymphoma of the stomach].
Topics: Amoxicillin; Biopsy; Combined Modality Therapy; Female; Follow-Up Studies; Gastrectomy; Helicobacter | 1998 |
Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Drug Therapy, Combination; Female | 2000 |
Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Cell Transformation, Neoplastic; Fem | 2001 |
Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Biopsy; Clarithromycin; DNA, Bacterial; Dru | 2001 |